NASDAQ:FMI Foundation Medicine (FMI) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free FMI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$137.00▼$137.0050-Day Range N/A52-Week Range$31.70▼$137.20VolumeN/AAverage Volume621,352 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Foundation Medicine alerts: Email Address Ad Behind the MarketsThe Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.Get the full story here >>> About Foundation Medicine Stock (NASDAQ:FMI)Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.Read More Ad DTImy top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.Click Here for this Powerful Workshop FMI Stock News HeadlinesMarch 19, 2024 | msn.comFoundation Medicine consolidates employees in new Seaport headquartersMarch 6, 2024 | tmcnet.comFoundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 28, 2024 | time.comMedicine: It WorksFebruary 27, 2024 | msn.comPrisma Health Midlands Foundation begins $2 million campaign for new and improved diabetic facilitiesFebruary 22, 2024 | msn.comArgentine austerity anger mounts, but govt says its workingFebruary 20, 2024 | forbes.comSupermarkets Lead On Food And Nutrition Initiatives, Study SuggestsFebruary 19, 2024 | forbes.comSupermarkets At Center Of Food As Medicine According To New StudyMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! January 25, 2024 | businesswire.comCystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CFJanuary 19, 2024 | msn.comCompanies You Didnt Know Were Military ContractorsJanuary 18, 2024 | msn.comThe Largest US Military Contractors in Every StateJanuary 11, 2024 | bizjournals.comWinter Park Health Foundation CEO to retireJanuary 8, 2024 | msn.comGroup practice opening in former South Bend Medical Foundation buildingDecember 14, 2023 | bizjournals.comLongtime Roche executive to lead subsidiary Foundation MedicineDecember 14, 2023 | finance.yahoo.comFoundation Medicine Appoints Dan Malarek as Chief Executive OfficerDecember 14, 2023 | businesswire.comAnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 InhibitorNovember 18, 2023 | businesswire.comFoundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug CombinationsNovember 15, 2023 | finance.yahoo.comFoundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung CancerOctober 21, 2023 | businesswire.comFoundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory FilingsOctober 20, 2023 | businesswire.comNew Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown ...October 19, 2023 | businesswire.comFoundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual MeetingAugust 24, 2023 | finance.yahoo.comWhole Exome Sequencing Global Market Report 2023August 23, 2023 | msn.comThe WHO Under Fire for Promoting ‘Pseudoscientific’ MedicineAugust 15, 2023 | msn.comPenn Medicine residents and fellows want a union, citing grueling workloads and 80-hour workweeksAugust 3, 2023 | thestreet.comFoundation Medicine (FMI) Stock Gains Today on Merger AnnouncementJuly 31, 2023 | news.yahoo.comDCH Family Medicine Dallas Center holds ribbon cutting ceremonySee More Headlines Receive FMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foundation Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:FMI CUSIPN/A CIK1488613 Webwww.foundationmedicine.com Phone617-418-2200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Troy Cox (Age 54)CEO, Pres & Director Mr. Michael Doherty (Age 59)Head of Product Devel. Mr. Jason Ryan (Age 44)Chief Financial Officer Mr. Konstantin Fiedler (Age 52)Chief Operating Officer Mr. Tom GoddenChief Information OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All Competitors FMI Stock Analysis - Frequently Asked Questions How were Foundation Medicine's earnings last quarter? Foundation Medicine, Inc. (NASDAQ:FMI) released its quarterly earnings data on Wednesday, May, 2nd. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.08. The business had revenue of $52.84 million for the quarter, compared to analysts' expectations of $44.99 million. Foundation Medicine's revenue for the quarter was up 100.7% compared to the same quarter last year. During the same period last year, the company earned ($1.31) earnings per share. What other stocks do shareholders of Foundation Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Foundation Medicine investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Gilead Sciences (GILD), HP (HPQ), Inovio Pharmaceuticals (INO), Viveve Medical (VIVE), Exact Sciences (EXAS), GW Pharmaceuticals (GWPH), NVIDIA (NVDA) and QUALCOMM (QCOM). This page (NASDAQ:FMI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foundation Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.